©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Adalimumab and pharmacokinetics: Impact on the clinical prescription for inflammatory bowel disease
Anne-Laure Pelletier, Department of Hepato-gastroenterology, Hôpital Bichat-Claude Bernard, 75018 Paris, France
Pascale Nicaise-Roland, Department of Immunology Autoimmunité et Hypersensibilités, Hôpital Bichat-Claude Bernard, 75018 Paris, France
Author contributions: All authors contributed equally to this paper with literature review, analysis, drafting and critical revision, editing and final approval of the final version.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or the coauthor who contributed their efforts in this manuscript.
Correspondence to: Anne-Laure Pelletier, MD, Hospital Practitioner, Department of Hepato-Gastroenterology, Hôpital Bichat-Claude Bernard, 46 rue Huchard, 75018 Paris, France. anne-laure.pelletier@bch.aphp.fr
Telephone: +33-1-40257200 Fax: +33-1-40258783
Received: September 22, 2015
Peer-review started: October 6, 2015
First decision: October 27, 2015
Revised: November 19, 2015
Accepted: December 13, 2015
Article in press: December 14, 2015
Published online: March 9, 2016
Processing time: 163 Days and 16.2 Hours
Peer-review started: October 6, 2015
First decision: October 27, 2015
Revised: November 19, 2015
Accepted: December 13, 2015
Article in press: December 14, 2015
Published online: March 9, 2016
Processing time: 163 Days and 16.2 Hours
Core Tip
Core tip: We have reviewed all the recent data about the factors that influence Adalimumab pharmacokinetics and the impact for the clinicians in the assessment of inflammatory disease. We looked at the inter patient variability, the drug clearance, antibodies detection, the effect of concomitant use of immunosuppressive.